Tailwinds' Take: this press release has a big "WOW" factor. If the market was looking for validation of Tru Niagen, Nestle can certainly provide that. CDXC has always seemed expensive unless Niagen takes off as a "must...
This week saw several extraordinary events come together simultaneously. On Tuesday the market dipped to the 4th largest point loss in Dow history. Wednesday saw markets closed (thankfully) in honor of the late...
hird Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%; TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60% Gross profit as a percentage of...
ChromaDex (CDX) is known by investors as the manufacturer of Nicotinamide Riboside, more commonly referred to as NR, an anti-aging nutraceutical. They are also known for owning the patents around NR. CDX was also the first and only company to...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
Shares in Chromadex were hit hard today, losing over 9% and closing at levels not seen since early July. This action in the stock was the direct result of SEC charges being levied against Phillip Frost, a holder of...
IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today second quarter 2018 financial results. Second Quarter 2018 Highlights...
IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the expansion of its partnership with A.S. Watson Group until September 2021,...
IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus...
Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on the stock. Summer doldrums will likely be your buying opportunity here. IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE)...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.